Albireo Pharma has submitted odevixibat approval for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC)
Albireo Pharma has submitted odevixibat approval for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC) to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) The US-based biopharmaceutical company has…
